Subsequent malignancies after allogeneic hematopoietic stem cell transplantation
Erişim
[Belirlenecek]Tarih
2017-04-11Yazar
Gündüz, MehmetÖzen, Mehmet
Şahin, Uğur
Toprak, Selami Koçak
Bozdağ, Sinem Civriz
Yüksel, Meltem Kurt
Arslan, Önder
Özcan, Muhit
Demirer, Taner
Beksaç, Meral
İlhan, Osman
Gürman, Günhan
Topçuoğlu, Pervin
Üst veri
Tüm öğe kaydını gösterÖzet
We evaluated 979 patients for the development of post- transplant lymphoproliferative disease (PTLD) and solid malignancies after allogeneic hematopoietic stem cell trans-plantations (allo- HSCT) as a late complication. We found 15 (1.5%) subsequent malig-nancies; three of these malignancies were PTLD, and twelve were solid tumors. The median time from allo- HSCT to the development of PTLD was 9 (3- 20) months and that from allo- HSCT to the development of solid tumors was 93 (6- 316) months. The cumu-lative incidence of evolving subsequent malignancy in patients was 1.3% (±0.5 SE) at 5 years and 3.9% (±1.2 SE) at 10 years. The cumulative incidence of developing subse-quent malignancy in patients with benign hematological diseases as the transplant indi-cation was 7.4%±4.2 SE at 5 years. More subsequent malignancy developed in patients having ?1 year chronic graft- vs- host disease (GVHD; 3.7% in ?1 year chronic GVHDand 0.7% in <1 year chronic GVHD patient groups, P=.002). Subsequent epithelial tumor risk was higher in ?1 year chronic GVHD patients than <1 year (3.7% vs 0.1%,P<.001). In multivariate analysis, benign hematological diseases as transplant indication (RR: 5.6, CI 95%: 1.4- 22.3, P=.015) and ?1 year chronic GVHD (RR: 7.1, 95% CI: 2.3- 22.5, P=.001) were associated with the development of subsequent malignancy.